Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PHAR 255 Exam 1 > Renal 2 > Flashcards

Renal 2 Flashcards

1
Q

Epidemiology of CKD in Canada

A

1 in 10 Canadians live with CKD (~ 4 million people)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the leading cause of CKD?

A

Diabetes is the leading cause of CKD (38%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Canada and ESRD Stats

A

End-stage renal disease ↑ 35% since 2009

In 2018, CKD was the 10th leading cause of death in Canada

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Can CKD be managed within primary care?

A

YES

95% of patients living with CKD are managed in primary care

Most people with CKD are asymptomatic

Appropriate to manage in primary care of CKD –> Send of those who have more substainial CKD to nephrologist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Clinical practice guidelines are developed by…… Key consideration of the interpretation of the guidelines?

A

KDIGO
Kidney Disease Improving Global Outcomes
Established 2003
International volunteer organization

KDOQI
Kidney Dialysis Outcomes and Quality Initiative
Established 1997
National Kidney Foundation (US)

Canadian Society of Nephrology
Guidelines updated in 2008 – CMAJ

Many of the recommendations are based on opinion or limited evidence given the lack of RCTs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Define CKD. What is it charcterized by and briefly discuss its progression?

A

Progressive loss of function occurring over several months to years

Characterized by gradual replacement of normal kidney architecture with fibrosis

Ultimately can progress to the point when dialysis or kidney transplantation is required
“End-stage renal/kidney disease” (ESRD or ESKD)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

CKD is a leading cause of _________ in North America because of……

A

A leading cause of morbidity and mortality in North America due to:

Progressive loss of kidney function
–>Complications
–> Eventually require RRT

Cardiovascular disease
Leading cause of mortality

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the leading cause of mortality regarding CKD? Stats?

A

Cardiovascular disease
–> Leading cause of mortality

50% of deaths of those with CKD are a result of cardiovascular disease (arrythymia or death)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are some causes of CKD?

A

The two main causes of CKD are diabetes and HTN, which are responsible for up to two thirds of all cases

Immune and inherited causes as well a other reasons are responsible;e for the rest

Not one disease in isolation; an umbrella term that captures kidney dysfunction and the numerous conditions that may lead to it

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are some high risk CKD populations?

A

Hypertension (HTN)
Diabetes Mellitus
Cardiovascular Dx
First degree relative with CKD
First Nations, Inuit, Metis or urban indigenous people(s)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the relationship between Indigenous people and the prevalence of CKD?

A

Indigenous Peoples are disproportionately affected by DM and related complications

2.6 times higher rate of ESRD or death in First Nations vs. non-First Nations persons diagnosed with DM prior to the age of 20

The WHO has recognized colonization as the most significant social determinant of health affecting Indigenous Peoples worldwide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

The clinicical definition of CKD is…..

A

Kidney function
GFR ≤ 60 mL/min/1.73m2 for 3 months or more,
with or without kidney damage

OR

Kidney structure
Kidney damage for ≥ 3 months, with or without decreased GFR, as evidenced by pathological abnormalities, abnormalities in blood or urine, or as seen by renal imaging

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the issue with defining CKD just based off of kidney function (GFR)

A

** Remember low eGFR may be explained by an AKI – may need to rule-out **

Impairment for 3 months or longer –> two tests

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Criteria for CKD:

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Screening of CKD algorithm

A

Recommended to order a lab panel of GFR should be done annually

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe the rate of decline of GFR

A

GFR ↓ by approximately 1 mL/min/1.73 m2/year beginning in the fourth decade of life (AT THE AGE OF 30)

65 yo ~50–60 mL/min.
80 yo ~30–40 mL/min.

GFR will ↓ to < 60mL/min in 5-25% of otherwise healthy adults due to aging alone (with no risk factors) –> NOT PREVENTABLE OR TREATABLE

Significant debate regarding labeling of patients >70 yo with mild to moderate reductions in GFR with no albuminuria and no hematuria as having “CKD”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What are some risks associated with CKD in older adults?

A

Reduced GFR due to age alone is not without risks:

Higher risk of AKI

Medication accumulation with reduced GFR (need for renal dose adjustments)

Reduced reserves in the event other comorbidities develop over time (e.g., DM)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Describe the staging of CKD based off of GFR:

A

G1 and G2 are not apart of CKD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Describe the staging of CKD based off of albuminuria:

A

A1 is not diagnostic of CKD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Regarding GFR and albuminuria classification, what is something that should be considered?

A

Regardless of the disease state causing CKD, the staging applies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Why is screening of CKD is important?

A

CKD is often asymptomatic
–> Importance of screening

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Describe the onset of sx of CKD

A

Symptoms generally minimal in stages 1-2 and ↑ incidence in stages 3-4

Low energy, fatigue, confusion
Foaming, tea-coloured, blood or cloudy urine
Edema
Shortness of breath
Pruritis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Describe the onset of CKD and diabetes

A

First sign of CKD is albuminuria even when GFR is fine

Happens when sugars are poorly controlled; why we have the ability to diagnose both ways

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Describe an overview of the care facilities in which CKD is managed

A

eGFR 30-59 mL/min (Stage 3a – 3b) –>usually managed in primary care

eGFR <30mL/min (Stage 4 – 5) –> usually managed in consultation with a nephrologist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Overview of Care for CKD

A

Delay progression of CKD
CV risk reduction
Treat complications of CKD
Renal replacement therapies (RRT)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Are all causes of CKD progressive?

A

Once CKD develops, it generally progresses over time

Autoimmune CKDs may undergo remission (e.g. lupus)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Describe the rate of decline of GFR in CKD

A

Rate of GFR decline highly variable from one individual to another

Average rate of decline between 2.3 to 4.5 mL/min/1.73m2 per year in the MDRD study

Lower GFR and greater albuminuria are both associated with a faster rate of progression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What is the general concept around GFR decline in tx of CKD?

A

Can slow the progression; cannot truly prevent the progression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Besides GFR, the rate of CKD progression also depends on…… Examples and rates?

A

Rate of progression also related to etiology of CKD

Diabetic nephropathy (with proteinuria occurs even faster), glomerular diseases, polycystic kidney disease, and kidney disease in transplant recipients tend to progress more quickly

Hypertensive kidney disease and tubulointerstitial diseases tend to progress more slowly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

What are some non-modifiable factors associated with faster progression of CKD?

A

Non-modifiable:

African-American race
Male gender
Advanced age
Family history

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

What are some modifiable factors associated with faster progression of CKD?

A

Modifiable:
Uncontrolled hypertension
Poor blood glucose control
Proteinuria
Smoking
Obesity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

What are some interventions to delay the progression of CKD?

A

Blood pressure control

RAAS blockade
–> ACE-i/ARB therapy
–> Non-steroidal MRAs

Blood glucose control in people with DM
–> SGLT2 inhibitors
–> GLP-1 agonists?

Smoking cessation

Avoidance of nephrotoxins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

What is the relationship between hypertension and CKD?

A

Hypertension can be both a cause and a consequence of CKD

Develops in 60-90% of pts with CKD at any stage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Hypertension is associated with what in CKD? How is this managed?

A

Associated with faster progression of CKD as well as cardiovascular disease

Strict blood pressure control delays progression of CKD

Untreated HTN –> decline in GFR 12 mL/min/year

BP<130/80 –> decline GFR 1-2 mL/min/year

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Describe the rate of decline in GFR as it relates to specific blood pressure values

A

Untreated HTN –> decline in GFR 12 mL/min/year

BP<130/80 –> decline GFR 1-2 mL/min/year

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

What are the blood pressure targets according to Hypertension Canada? What are these targets based off of?

A

<130/80 for patients with diabetic CKD

SBP <110 for adults with polycystic kidney disease

SBP <120 for “high risk” patients*

SBP <140 for “all other patients”

-Starredis based off of SPRINT trial

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

What are the KDIGO blood pressure targets?

A

SBP <120 for patients with high BP and CKD (not on dialysis), when tolerated (using standardized office BP measurements)

<130/80 for kidney transplant recipients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

In the SPRINT trial, what was excluded from the inclusion criteria?

A

Diabetes Melitus

Looked at AARF

Age >75
Arthersclerosis
Renal CKD
Framinham Risk Score >15%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

What is the benefit of the ACCORD trial?

A

ACCORD trial looked at more intensive of BP targets in diabetics (120 and 140)

Also looking at more aggressive A1C targets

No benefit to pursuing less than 120 and may result in harm in those folks

ACCORD did not recruit many patients with CKD because SCr >1.49 mg/dl was an exclusion criterion.

.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

ACCORD Trial and KDIGO

A

More aggressive targets in diabetics

Looked at the subset of those with those with normal A1C targets, they did notice that more intensive lowering was beneficial (clouded in those with more aggressive lowering of A1C)

WhyKDIGO recommends less than 120 in those with diabetes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

What trial was used in the development of HTN Canada Guidelines? Describe the hypertension Canada guidelines according to specific dx states?

A

SPRINT TRIAL

Patients meeting SPRINT criteria: <120 mmHG

Patients with Adult Polycystic CKD <110

All other patients with non-diabetic CKD <140

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Critical consideration in the hypertension guidelines regarding blood pressure targets

A

A BP target may be individualized at the discretion of the physician considering:

a) Pt’s Specific Kidney Disease
b) Comorbidities
c) Age

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

What are some clinical indications for a systolic target of <120 according to the canadian hypertension guidelines?

A

a) Clinical or subclinical CV dx

b) CKD (non-diabetic nephropathy, proteinuria < 1 g/d, eGFR 20-59 ml/min/1.73 m2)

c) Framingham Risk Score > or = to 15%

d) Age > or = to 75

Patients with 1 or more clincial indications should consent to intensive tx

AARF

Age >75, artherosclerosis, CKD, Framingham >15%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

What are some cautions for pursuing a SBP of <120?

A

Limited or No Evidence:

a) Heart Failure (LVEF < 35%) or recent MI in last 3 months

b) Indication for, but not currently recieving, a Beta-Blocker

c) Institutionalized elderly

Inconclusive Evidence :
a) Diabetes Mellitus

b) previous Stroke

c) eGFR <20 ml/min/1.73 m2 (Including dialysis and transplant pt’s)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

What are some C.I. to pursuing a SBP of less than 120?

A

Patient unwilling or unable to adhere to multiple medications

Standing SBP <110 mmHg

Inability to measure SBP accurately

Known secondary cause(s) of HTN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

According to the SPRINT trial, what were some reasons favouring a SBP target of less than 120?

A
  1. The potential benefits are clinically meaningful (Statistical significance in composite endpoint of CV events and all cause mortality)
  2. The CV and mortality benefit may make it worth trouble shooting tolerability and adverse event risks for some patients.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

According to the SPRINT trial, what were some reasons against a SBP target of less than 120?

A

There are potential harms which must be weighed against the potential benefits including:

a) Syncope
b) Hypotension
c) Electrolyte abnormality
d) Acute renal failure
e) More CKD progression

A large number of the cases against SBP target is due to hemodynamic changes (change to renal blood flow and not actually damages to the kidneys itself)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

Who may be suitable for a SBP target of <120?

A

Age >50 yo

W/out a high degree of comorbidity

Achieve BP control w/out requiring a large # of antihypertensives

Do not have issues with adverse effects

–> Those under 50 may still benefit; absolute risk reduction is highe rin those who are older

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

Who is not suitable for a SBP<120?

A

Age >90 yo, or living in a nursing home

Requiring > 3 antihypertensives to get to target

At risk of falls from postural hypotension

DBP < 60 mmHg (↑ MI risk?)

SBP 120-129 mmHg

Severe HTN (SBP > 180 mmHg)

Those who feel the benefits are not worth the risks, costs, effort

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

Lifestyle recommendations for lowering BP by HTN Canada?

A

Salt restriction: Reduce sodium intake towards 2,000mg (5g of salt) per day

Exercise: 30-60 minutes moderate intensity 4-7 days/week, in addition to the routine acts of daily living (higher intensities no more effective)

Weight reduction in overweight/obese pts
BMI 18.5-25 kg/m2 recommended

Limit alcohol consumption: 1-2 drinks/day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

Describe the importance of lifestyle modifications in reducing BP as it relates to CKD?

A

NON-PHARM TX MUCH MORE IMPORTANT IN PT”S WITH CKD

Can be more beneficial than a drug and can decrease proteinuria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

Blood pressure control in CKD can be difficult because….

A

Often require 3-4 drugs to control BP, especially as kidney disease progresses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

First line options for blood pressure control per KDIGO? Considerations by pharmacists?

A

First-line options per KDIGO:

ACE-i/ARBs
diuretics
long-acting CCBs

Consider comorbidities, stage of CKD, degree of albuminuria, type of CKD when selecting therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

What is the first line tx for HTN if a patient has proteinuria?

A

ACEi and ARBs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

Describe the RAAS pathway and where ACEi and ARBs work

A

Angiotensin Coverting Enzyme released by lungs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

Acei and ARB MOA in CKD

A

Reduce BP and glomerular capillary pressure
–> By selectively vasodilating the efferent arteriole

Reduce proteinuria more than any other antihypertensive
–> After accounting for the effect of BP lowering on protein excretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

What is unique about ACEi and ARBs in CKD?

A

Reduce proteinuria more than any other antihypertensive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

How do ACE i and ARBs decrease proteinuria? This drives what decision?

A

Takes pressure off the glomerulus

Independent of BP lowering effects, ACE-I and ARBS reduce proteinuria by reducing pressure in the glomerulus

May even be used in those with CKD who have good BP control

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

Overall outcomes of ACEi and ARBs therapy in CKD?

A

Improvement in:

Kidney outcomes (e.g., reduced risk of kidney failure, doubling of SCr, GFR decline, progression of albuminuria)

CV outcomes demonstrated by multiple RCTs (e.g., IDNT, RENAAL, HOPE)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

HTN Canada and KDIGO recommend an ACEi or ARB as….

A

First-line therapy for kidney diseases with albuminuria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

When should an ACE/ARB be initiated in certain people according to HTN Canada and KDIGO?

A

Diabetic kidney disease – if ACR > 3mg/mmol (category A2, aka microalbuminuria)

Nondiabetic proteinuric CKD – if ACR > 30mg/mmol (category A3, aka macroalbuminuria)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

Is there preference given to an ACEi or ARB?

A

No. Can be used interchangeably.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

What are some contraindications for ACEi/ARB therapy?

A

Angioedema
Bilateral renal artery stenosis
Pregnancy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
64
Q

What is the concern with bilateral renal artery stenosis and ACE/ARB therapy?

A

Angiotensive 2 is protective of the kidney
–> allows filtration to occur and maintains perfusion especially in bilaterial renal artery stenosis

May see rises of SCr of greater than 30% in bilateral renal artery stenosis

DO not use

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
65
Q

What are precautions for ACEi/ARB therapy?

A

Intravascular fluid depletion
–> Reduce/hold dose if severe vomiting, diarrhea, fluid depletion (May not be able to maintain perfusion)

eGFR <30mL/min/m2

Hypotension (caution if BP <110/70)

Hyperkalemia (K+ > 5.5 mmol/L) (inhibit the production of aldosterone; helps maintain K+, can see a rise in K+)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
66
Q

What are the monitoring parameters of ACE/ARB therapy?

A

2-4 weeks following initiation, or any dose ↑

SCr
↑ SCr > 30% from baseline may warrant discontinuation

Potassium (3.5-5mmol/L)
If high: restrict dietary K+, add diuretic

Blood pressure
Assess target achievement

Urinary Albumin: Creatinine Ratio (ACR)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
67
Q

How critical is the monitoring of ACE/ARB therapy in CKD?

A

CRITICAL IN CKD

VULNERABLE TO INCREASES HERE

MONITORING BECOMES IMPORTANT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
68
Q

If a patient is experiencing hyperkalemia, the pharmacist should….

A

DO EVERYTHING WE CAN TO REDUCE K+ BY OTHE RMECHANISMS RATHER THA STOPPING AND ACEI OR ARB

KEEP THEM ON BOARD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
69
Q

Describe the algorithm for monitoring of SCr and K+ in CKD for ACE/ARB therapy?

A

KDIGO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
70
Q

How are ACE/ARB’s dosed in CKD? Consideration?

A

Start at a low dose and titrate to maximum tolerated dose (or the highest approved dose

May have achieved targets of BP, may increase further to reduce proteinuria as much as possible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
71
Q

ACE/ARB Therapy Dose relationship with CKD progression

A

Dose-dependent reduction in the albuminuria lowering effect (and the risk of progression of CKD)

Side effects are also dose related

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
72
Q

When selecting an ACEi or ARB, which ones should are choosen? Example?

A

If renally eliminated, must take into consideration

Monographs provide recommendations for decreased kidney function. Do not necessarily stop if kidney function is below and stable .

Perindopril –> if 25 ml/min(Do not use ifCrCl below 30) DO NOT STOP if kidney function is stable and doing well (DO NOT AUTOMATICALLY SWITCH ACE OR ARB BASED OFF WHAT THE MONOGRAPH IS SAYING)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
73
Q

ACEi end in….

A

PRIL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
74
Q

ARBs end in

A

SARTAN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
75
Q

Combination of ACE/ARB Therapy Recommendations. Why is this recommendation good or bad?

A

Combination of ACE-i + ARB used to be recommended for CKD with refractive proteinuria

Now, KDIGO recommends avoiding any ACE-i/ARB combination

Telmisartan, ramipril or both for preventing dialysis, renal transplant, doubling of SCr, or death

Combination superior for reducing proteinuria and BP, but actually worsened renal outcomes (hyperkalemia, need for acute dialysis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
76
Q

A direct renin inhibitor is…..

A

Aliskiren

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
77
Q

Aliskren Evidence for Use in CKD

A

Early trials - Alikirsen combination with ARBs, diuretics
Showed reduction in proteinuria

ALTITUDE TRIAL

patients with T2DM and proteinuria or CVD with reduced kidney function being treated with ACE-i or ARB

Measured CV and renal morbidity and mortality, compared with placebo, when added to conventional treatment (including ACE-i or ARB)

Aliskiren arm had more frequent adverse events, including non-fatal stroke, renal complications, hyperkalemia and hypotension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
78
Q

Aldosterone Antagonists (MRA’s)- Spironolactone Evidence in CKD

A

Mainly spironolactone + ACE/ARB in CKD (+/- DM) - Cochrane Review

Findings:
Reduced proteinuria 30-40%
Improved BP
Possible slowing of CKD progression (GFR decline)
No CV/ESRD outcomes (Not long enough to evaluate)
Doubled risk of hyperkalemia
5-fold risk of gynecomastia

Use of MRA’s limited to those who had another indication for it e.g. heart failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
79
Q

Steroidal MRA’s are also known as….. Examples

A

Steroidal (aka non-selective)

Spironolactone, eplerenone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
80
Q

Non-steroidal are also known as….. Examples. MOA and use in CKD?

A

Non-steroidal (aka selective)

Finerenone

Much higher specificity for MR vs. glucocorticoid/androgen receptors

Reduction in albuminuria, while having less side effects (such as gynecomastia)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
81
Q

MRA Usage in DM Recommendation by KDIGO

A

Use non-steroidal MRA with proven kidney or CV benefit for patients with T2DM, an eGFR > or = 25 mL/min, normal K+ levels, and albuminuria (ACR > or = 3) despite maximum tolerated dose of a RAASi

–> Eligibility in trials was K+ < 4.8

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
82
Q

MRA usage in HTN Recommendation in KDIGO

A

Possible use in refractory HTN (uncontrolled on 3 other drugs including a diuretic), with GFR >45 mL/min

All about blood pressure control (not a strong recommendation; a consideration)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
83
Q

What was the main finding of the FIDELO-DKD trial?

A

The most concerning a/e of Finerenone was hyperkalemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
84
Q

According to KDIGO DM recommendations of MRA usage, what are the guidelines for therapy regarding K+ lab values?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
85
Q

What are some limitations of Finerenone

A

Not currently covered by SK drug formulary or NIHB
–> Approved by Health Canada October 2022, under brand name Kerendia

Less evidence available in patients also taking a SGLT2i
–> Benefits of finerenone appear to remain (indications but less confidence due to lack of evidence)

Not to use in combo with steroidal MRAs in patients with HF (and not to replace steroidal)
–> Lack of evidence and guidance to inform this decision; dependent on stage of HF (if less severe, may lean to use finerenone)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
86
Q

Why are diuretics used in CKD?

A

Fluid retention is an important contributor to hypertension in CKD

Most patients require diuretic therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
87
Q

Describe the initiation of a diuretic in CKD

A

Start with thiazide – might hear debate over efficacy once GFR<30 mL/min (stage G4-G5 CKD) –> may look to switch someone to a loop diuretic; may provide some blood pressure benefit through another mechanism at threshold of 30 ml/min

May switch to or combine with loop diuretics for volume control or if BP becomes resistant to therapy

May prefer combo with metolazone, chlorthalidone, or indapamide (effective diuresis at GFR<30 mL/min)

Generally avoid potassium-sparing diuretics in stage 3-5 CKD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
88
Q

Describe the CLICK trial

A
  • Evaluated chlorthalidone efficacy vs placebo in stage 4 CKD (GFR 15-30 ml/min)
  • 75% of people had T2DM
  • Signficiant improvement in BP, 30-40% reduction in ACR
  • Caveat: Short trial (12 weeks long) and did not look at hard endpoints
  • Risks: Watch for electrolyte disturbances (e.g. hypok+) and orthostasis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
89
Q

Describe when a pharmacist would recommend a switch from hydrochlorothiazide to chlorthalidone

A

Hydrochlorothiazide signifificantly less potent than chlorthalidone (tzd)

If looking to start a diuretic on someone at 30 ml/min, start chlorthalidone

If GFR above 30 and good blood pressure control, would not likely switch them to chlorthalidone if on hydrochlorothiazide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
90
Q

CCB used in CKD

A

DHP-CCB’s - e.g. Amlodipine

Non-DHP CCBs - Diltiazem, Verapamil

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
91
Q

DHP-CCB use in CKD

A

Preferred to thiazides in combo with ACE-i/ARB in patients with diabetes, given CV benefits (ACCOMPLISH TRIAL)

No evidence for slowing CKD progression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
92
Q

DHP-CCB A/E in CKD

A

May cause fluid retention and edema (problematic in CKD patients)

Pedal edema; peripheral vasodilation, leakage into extravascular peripheral space (NUISANCE SIDE EFFECT; NOT A BIG PROBLEM)

93
Q

NON-DHP CCB Use in CKD

A

Shown to decrease proteinuria, but not to same extent as ACEIs

Not preferentially used for reducing proteinuria, but may provide benefit when added to ACE-i/ARB

No evidence for slowing CKD progression

94
Q

Tolerability and Safety Issues with Non-DHP CCB’s

A

constipation and bradyarrhythmia

(particularly in combo with BBs)…lots of DIs, CIs

95
Q

Dose Beta-Blocker in CKD

A

Renally eliminated BBs may require dosage adjustment once CrCl approaches 30 mL/min

E.g., atenolol, bisoprolol

96
Q

Monitoring of Beta-Blockers

A

Monitor HR and BP for signs of accumulation

97
Q

Common s/e of Beta-Blockers

A

Common S/E: fatigue, limited exercise tolerance

98
Q

Why are beta-blockers used in CKD?

A

Inconsistent evidence that BB have evidence in CKD pt’s

Use if HF, Post MI, Angina

99
Q

Alpha 2- Agonist Example

A

clonidine

100
Q

Alpha-2 Agonist Use in CKD.WHy?

A

Valuable as adjunctive therapy for HTN b/c no DIs with commonly used BP meds

Blood pressure hard to control in later stages of CKD

101
Q

Alpha 2 Agonist Precautions

A

Usual precautions due to CNS side effects (e.g., elderly)

Risk of rebound HTN if stopped abruptly (taper if discontinued)

102
Q

Alpha-1 Blocker Examples

A

terazosin, prazosin

103
Q

Alpha-1 Blocker Usage in CKD

A

Adjunctive treatment for elevated BP in CKD patients

Might consider in patient with prostatic hypertrophy (BPH)

104
Q

Alpha-1 S/E

A

Common S/E: dizziness, orthostatic hypotension

105
Q

Direct Vasodilator Example

A

Hydralazine

106
Q

Direct Vasodilator Usage in CKD

A

Might be used as adjunct

Use is limited by side effects (e.g., headache, fluid retention)

107
Q

Are SGLT-2i used in CKD for BP management?

A

Have some blood pressure benefit; not the main reason for why we use

108
Q

Which agents used for BP management have an effect on CV or kidney function despite BP management?

A

ACEi
ARB’s
NON-DHP CCB
Direct Renin Inhibitors
MRA’s

All reduce proteinuria

109
Q

Which agents used for BP management have an effect on kidney function? Mechanism?

A

ACEi
ARB’s
NON-DHP CCB
Direct Renin Inhibitors (if not tolerating ACEi or ARB)
MRA’s

All can reduce proteinuria

110
Q

What is the relationship of proteinuria with CKD? CV DX?

A

Is linked with progression of diabetic and non-diabetic CKD

High risk of progressing to kidney failure

An indicator of subclinical cardiovascular disease

111
Q

What category is micoralbuminuria classified as?

A

Category A2 albuminuria

112
Q

What is the relationship between Micoralbuminuria and CKD progression? Why is this critical?

A

Predicts loss of kidney function

Important to identify patients at this stage so appropriate therapy (ACE-i or ARB) can be instituted to slow progression

113
Q

Why is proteinuria damaging to the kidneys?

A

Cellular damage, damage to glomerulus, protein is toxic to the tubules

114
Q

What is the definition of proteinuria? What proteins is it?

A

Proteinuria: > 150 mg protein lost in urine per day

Can be albumin OR other plasma proteins

115
Q

Describe the classification of proteinuria

A

Mild (150–500 mg) = Category A2

Moderate (>500 mg) = Category A3

Nephrotic range (more than 3000 mg = 3 grams or albumin excretion > 2200 mg/24h)

116
Q

What is the normal amount of protein lost in the urine throughout the day?

A

40-80 mg per day is a normal amount of protein in the urine

117
Q

Why are proteins in the plasma critical?

A

Protein through osmotic effect maintains fluid in vasculature; lose proteins in urine, decrease blood pressure

118
Q

What is nephrotic syndrome?

A

Associated with hyperlipidemia, hypoalbuminemia, generalized edema, thromboembolic risk (Anti-thrombin 3 lost in urine- clot risk increases)
foamy urine

119
Q

What are some examples of kidney diseases associated with proteinuria? TX?

A

Diabetic nephropathy
Hypertensive kidney disease
Primary glomerular diseases (e.g., Minimal Change Disease, focal and segmental glomerulosclerosis, IgA nephropathy)
Lupus nephritis
Post-streptococcal glomerulonephritis

  • For many an ACEi or ARB may be appropriate; but may not be started right away
  • Many also treated with steroids or immunosuppressants
120
Q

Why may an ACEi or ARB be used in pt’s without HTN?

A

Reduce glomerular capillary pressure and volume (vasodilate efferent arteriol; less pressure; protective ebenfit)

Possible direct effect on podocytes to ↓ proteinuria

(Want to Reduce proteinuria in the absence of HTN because of the effect on the glomerulus)

121
Q

ACEi and ARBs indication

A

First-line therapy for kidney diseases with proteinuria (due to CV and kidney benefits)

Diabetic or hypertensive kidney disease with category A2 or A3 albuminuria
Other kidney diseases with proteinuria

122
Q

ACEi and ARB in patients with HTN and Proteinuria Monitoring

A

Monitor for hypotension

123
Q

DAPA_CKD Trial looked at….

A

Dapaglifozin 10 mg vs placebo in patients with CKD with or wt diabetes

124
Q

Findings of DAPA-CKD

A

Irrespective of diabetes:

Decline in ESRD and death from CV or renal dx (driven by preservation of eGFR)

Prevention of decline in eGFR > or = 50%

Decline in all cause mortality

Those without diabetes had no hypoglycemic risk

125
Q

DAPA-CKD Main A/e

A

Volume depletion

126
Q

What is an issue with the DAPA-CKD trial?

A

98% were on ACEi or ARB
65% were on a Statin

  • Difficult to determine the effect of dpaglifozin on its own
127
Q

Indication SGLT-2i in CKD (CCS) Why?

A

CanadianCardiovascular Society

    • Adults with ACR >20 mg/mmol and eGFR >or = 25%
  • Reduce significant decline in eGFR, ESRD, death due to renal dx or CV all cause CV mortality
  • reduce nonfatal MI and hospitlization for HF
128
Q

Bottom line of SGLT-2i usage in CKD

A

You will see prescriptions for SGLT2i in patients with CKD and withOUT diabetes!

To improve renal and CV outcomes

129
Q

Limitations of SGLT-2i use in CKD

A

Limitations: COVERAGE

Dapa has the best coverage on SK formulary (coverage for CKD without diabetes); NIHB open coverage

130
Q

what is the relationship between T2D and CKD?

A

40% of patients with T2DM have CKD

131
Q

Is screening for CKD recommended for diabetics? If so, when?

A

Screening for CKD in patients with diabetes:

Random urine ACR & SCr (and eGFR) should be checked at least annually in stable patients

Begin screening:
5 years after diagnosis of T1DM
At time of diagnosis for T2DM

132
Q

Is diabetes Canada guidelines on nephropathy the same as KDIGO?

A

NO

133
Q

CKD progression in Diabetes

A

Progresison is typically slow; 5 years in each stage

Slow at the beginning; 1-2 ml per year, accelerates in later years 5-10 ml per year –> Quickly leads to ESRD

  • Why screening is important
134
Q

Why is blood glucose control critical in diabetics?

A

Prevents and delays progression of diabetic nephropathy

135
Q

A1C targets for reducing CKD risk in Diabetics

A

Target A1C ≤7.0 for most patients

≤6.5 may be appropriate in some to ↓ CKD risk

136
Q

Why may an agressive A1C target be used? Risks?

A

Slow down other risks such as nephropathy however run the risk of hypoglycemia

New medications have a lower risk of hypoglycemia so may pursue more aggressive targets

137
Q

Issues with A1C Measurements in CKD

A

HbA1C measurements may be less accurate in patients with advanced CKD (~G4 – G5, particularly with dialysis)

Develop significant anemia, blood loss, etc.

138
Q

Why are higher A1C targets, such as 8, not useful in CKD?

A
  • KDIGO
  • Increase in severity of CKD
  • Macrovacular compl present
    Many commorbities
    Short life expectancy
    Impaired hypoglycemia awareness
    Scarce resources for hypogycmeia managment
    More risk of tx induced hypoglycemia
139
Q

KDIGO TX Algorithm for Diabetes

A
140
Q

Metformin Use in Diabetics with CKD

A

Evidence primarily for CV benefit

Lack of evidence for kidney protective effects other than lowering A1C (not kidney protective)

141
Q

What are some benefits of metformin?

A

Low risk of hypoglycemia, inexpensive drug, weight loss (bare minimum are weight neutral), good safety profile

142
Q

Diadvantage of Metformin

A

Requires Renal Dose Adjustments

  • Dose is lowered at a GFR of <45 ml/min
143
Q

Why does metformin require dose adjustments at a GFR below 45 ml/min? Exception?

A
  • Lactic Acidosis
  • High mortality rate

May see used in individuals with STABLE renal function with eGFR 15-29 ml/min (500 mg/day)

144
Q

SGLT-2i Evidence in Diabetics with CKD

A

Evidence for CV benefits AND for reducing the progression of CKD in patients with DM

CREDENCE 2019 (DM, albuminuria): canagliflozin

DAPA-CKD 2020 (+/- DM, albuminuria): dapagliflozin

EMPA-KIDNEY 2022 (+/- DM, +/- albuminuria): empagliflozin

145
Q

KDIGO reccomendation for use of SGLT-2i in Diabetes

A

1st line agent for patients with T2DM, CKD, and eGFR >20mL/min

  • Have not said to use in pt’s without diabetes yet
146
Q

SGLT-2i Benefit is independent of…..

A

Independent of glucose lowering effect

147
Q

What is the action of SGLT-2i on the kidney? Clinical implications?

A

Afferent arteriole narrowing leads to:

a) Decreased glomerular pressure
b) Reduction in albuminuria
c) Renal protection suggested

148
Q

What is the action of RAAS blockade on the kidney? Clinical Implications?

A

Efferent arteriole widening leads to:

a) Decreased glomerular pressure
b) Reduction in albuminuria
c) Renal protection proven in clinical trials

149
Q

What is the benefit of SGLT2-i and RAAS blockade on the kidney?

A
  • Afferent narrowing and efferent widening leads to:

a) Potential for normalization of intraglomerular pressure
b) Potential additive intraglomerular pressure reduction
c) Potential for long term renal protection

150
Q

Key Point of SGLT-2i usage in CKD

A

Guidelines recommend
SGLT2 inhibitors to improve
renal and CV outcomes,
regardless of the patient’s A1C
(even if targets are met)

151
Q

If we were to be worried about glucose in someone who had TD2M and CKD, what may we do?

A

Stop sulfonurea, gliclazide if worried about glucose and start an SGLT-2i

152
Q

Downfall of SGLT2-i in these pt’s who have CKD

A

Benefits unkown

T1DM
GFR <20 ml/min

153
Q

Dapaglifozin Dose and Kidney Function Approved by FDA

A

Dapa- 10 mg OD - eGFR > 25 ml/min/1.73 m2

154
Q

EMpaglifozin Dose and Kidney FUnction Approved by FDA

A

10 mg OD (Can increase to 25 mg OD if needed for glucose control)

eGFR > or = to 30 ml/min for T2DM and ASCVD; 20 ml/min for HF

155
Q

Canaglifozin Dose and FDA Approved Renal Function

A

100 mg OD

eGFR > or = 30 ml/min

156
Q

Main Considerations in Initiation of SGLT-2i in CKD

A

KDIGO

Not to be initiated if eGFR <20mL/min, but may be continued until dialysis

Can continue with a modest initial ↓ eGFR (≤30%)

157
Q

Dosing of SGLT-2i? Is a dose increase required?

A
  • Want to use the lowest dose possible for renal and CV benefits
  • Limited benefit to increasing dose (Exception: if needing glucose control)
158
Q

With an ARB, AcEi, or SGLT2-i, why may one notice an initial decrease in eGFR?

A

Similar to ACEi and ARB reduce pressure on glomerulus leading to an increase in serum creatinine; expect with SGLT2i

Hemodynammaic increase here

159
Q

Effect of SGLT2-i on Dialysis

A
  • Delays dialysis by 10 years if on SGLT2i
160
Q

Caniglifozin CI

A

eGFR <30 ml/min

161
Q

Dapaglifozin C.I.

A

eGFR < 25 ml/min

162
Q

EMpaglifozin C.I.

A

eGFR <20 ml/min

163
Q

Cautions of Initiating SGLT2-i. When to start?

A
  • Volume depletion
  • Active genital mycotic infection
  • Hypotension (blood pressure less than 95 mmHG)
  • Previous critical limb ischemia
  • DKA
  • Use of insulin or insulin secretagogues in those with GFR > or = 45 ml/min

DELAY INITIATION OF SGLT-2I UNTIL CONDITION RESOLVED/THERAPIES MODIFIED TO REDUCE RISK

164
Q

SGLT-2i drug-drug effects with:

A

Loop Diuretics

  • Optimal dose reduction if euvolemic
  • 30-50% dose reduction if volume depletion occurs (e.g. diziness)

Insulin or Insulin Scertagogue
- If DM with A1C < or = 8%, consider dose reduction (10-20% insulin or 50% secretagogue)
- if episodes of hypoglycemia, stop secretagogue and reduce insulin dose

165
Q

How do SGLT-2i work?

A
  • Eliminates glucose in the urine so risk of volume depletion (hypovolemia)
166
Q

SGLT2-i MOA, GFR and A1C relationship

A

As GFR drops, the ability to reduce A1C is also lowered (eliminating glucose in the urine)

167
Q

Common A/e of SGLT-2i

A

Thirst
Increased Urinary Frequency and Urine Volume
Genital Mycotic Infections
Hypovolemia
Light headnessness and postural hypotension
Diabetic ketoacidosis

168
Q

How can one reduce the risk of diabetic ketoacidosis?

A

Hold in acute sickness
SADMANS

169
Q

Can an SGLT-2i cause an AKI?

A

Risk is low and has not been well observed

Predispose the kidney to hemodynamic effects (pre-renal effects)

170
Q

GLP-1 Agonist Examples

A

“Glutides” Example: Semaglutide

Exenatide and Lixsenatide

171
Q

Use of GLP-1 agonists in CKD

A

Evidence for CV benefits and favorable kidney benefits

172
Q

GLP-1 Agonist and KDIGO Recommendation

A

Use if A1C targets not achieved with metformin/SGLT2i (or if one of these not tolerated)

173
Q

Benefits of GLP-1A Agonists

A

Weight Loss
Insulin Sparing
CV Benfits
Quite effective at lowering A1C

174
Q

A1C comparison between SGLT-2i and GLP-1 Agonist

A

GLP-1’s are quite effective at lowering A1C whereas SGLT-2i are less effective

175
Q

Limitations of GLP-1 Usage

A

Limited by cost; coverage is poor

Studies have been done for hardpoints have been done only with those with diabetics –> evidence only supports diabetics at the moment

176
Q

Medications used for blood glucose lowering that have cardiorenal benefits

A

SGLT-2i and GLP-1 agonists

  • The rest of the diabetic medications are a toss up; e.g. sulfonureas have no CV or renal benfit; main benefit is only A1C lowering
177
Q

Why is smoking cessation critical for CKD?

A

Smoking increases progression of CKD
Mechanisms: ↑ BP & HR, ↓ renal blood flow (constriction), vascular injury

Also is a risk factor for cardiovascular events

178
Q

Regarding CKD, a critcial factor is…… Examples include:

A

Avoid use of nephrotoxic drugs whenever possible
Examples:
NSAIDs, COX-2 inhibitors
lithium
aminoglycosides
amphotericin B
calcineurin inhibitors
cisplatin

Minimize/avoid radiocontrast dye

179
Q

What combination should be avoided in CKD?

A

Avoid combination of ACE-i/ARB, NSAIDs, and diuretic (“triple whammy”)

180
Q

What is sick-day management?

A

When patients with CKD become acutely ill and are unable to maintain adequate fluid intake (e.g., due to viral gastroenteritis), recommended to hold potentially nephrotoxic or renally excreted drugs

Sulfonureas
ACE inhibitors
Diuretics, direct renin inhibitors
Metformin
Angiotensin receptor Blockers
NSAIDS
SGLT2-i

181
Q

Why is sick day management critical?

A

Largely around the kidneys

Input does not equal the output; susceptible to pre-renal AKI’s

Hold drugs that are nephrotoxic or renally eliminated

Metformin and sulfonurea are on here; can accumulate if not cleared as primarily cleared by the kidney

182
Q

What is the leading cause of death in people with CKD?

A

Cardiovascular disease (CVD) is the leading cause of death in patients with CKD

Most patients with CKD will die from CVD before requiring RRT

183
Q

WHat should people with CKD be screened for? Examples?

A

Patients with CKD should be screened for CV risk factors and managed appropriately

Common CV risk factors: DM, dyslipidemia, HTN, LVH, smoking, obesity

184
Q

CKD and CV Risk reduction: Which is first?

A

Main focus: Slow CKD progression then reduce CV risks

185
Q

Guidelines for starting Statin in CKD

A

CanadianCardiology Society

Age > or = 50 yrs old and eGFR <60 ml/min
or
ACR > 3g/mmol

Start a high dose statin in CKD despite baseline LDL level

  • CKD is a statin indicated condition
186
Q

Key Point of Statin Use in CKD

A

Guidelines recommend a statin for most patients with CKD, regardless of their LDL

187
Q

KDIGO recommendations for the treatment of Dyslipidemia

A

> 50 years old with eGFR <60 & not on dialysis:
Tx with low-dose statin or statin/ezetimibe combo irrespective of LDL level

> 50 years old with CKD and eGFR >60:
Tx with statin

18–49 year old with CKD:
Tx with statin treatment if estimated CV risk is >10% (high) (e.g., prior CV event or diabetes)

If on dialysis: Do not initiate therapy - If already on therapy, continue it

Kidney transplant: Tx with a statin (in some cases)

188
Q

KDIGO Guidelines for Low or High Dose Statin

A

Stick with low dose statin

‘fire and forget’ strategy vs. ‘treat to target

  • Not dosing based off LDL target
189
Q

KDIGO Benefit of Statin Use

A

Benefit = CV risk reduction and mortality, no benefits to slowing CKD progression (entirely cardiovascular)

  • Relative risk similar in those with CKD and those without CKD; however, absolute risks in CKD group are higher so see a greater benefit
190
Q

Dosing of Statins in CKD Limitation

A

KDIGO Major limitation: Studies done on patients with dialysis

Evidence to support these doses are not based off the trials that apply to majority of CKD patients (small proportion that end up on dialysis)

Lacking good evidence to support using statins for primary prevention in majority of CKD population

191
Q

SHARP Trial Findings

A

SHARP trial – simvastatin vs ezetimide, not a good quality study – unclear benefit of ezetimide and never use as monotx, primary prevention trial)

192
Q

Jupiter Trial Findings

A

JUPITER trial –> Rosuvaststain –> 20% of pts had CKD (made some inferences off of that)

193
Q

Why does KDIGO recommend low dose statins?

A

More conservative route as lack evidence.

Some concerns about toxicity, question the lack of evidence supporting high dose ststains in CKD

194
Q

CCS Dyslipidemia Guidelines CKD Statin Use. Why?

A
  • High dose statin in all patients who meet the criteria for primary prevention (includes CKD)
  • Weak recommendation: Higher statin used, more benefit
195
Q

High Dose Statin Examples

A

Atorvastatin 40-80 mg HS
Rosuvastain 20-40 mg HS

196
Q

Which statins are hepatically eliminated?

A

Atorvastatin, lovastatin, and simvastatin

Hepatic Elimination (Concerns with Drug Interactions here)

197
Q

Renally Eliminated Statin

A

Rosuvastatin

198
Q

Can high doses of statins be used in CKD?

A

Doses can be used in all CKD pt’s even those with dialysis (studies in dialysis pt’s)

199
Q

When are statin’s dosed?

A

DOSE HS

Cholesterol synthesis primary throughout the night

200
Q

Statin Tolerability Issues

A

Muscle pain; want a dose they can tolerate it.
Want someone on a high dose; however, want someone on the highest dose they can tolerate as a statin at any dose is better than no statin

201
Q

Main Safety Concern WIth Statins

A

Main Safety Concern with Statin’s: Rhabomyolsis –> Can lead to AKI –> Risk of rhabo is extremely low

202
Q

When choosing a statin in CKD, one may lean towards ______ because ______

A

Atorvastatin; hepaticl elimination

203
Q

Does anti-platlet therapy have a role in CKD?

A

Low dose ASA (81 mg) has no role in primary CV prevention in patients with CKD

Would be used in secondary prevention (post-MI etc.)

204
Q

What are the different types of renal replacement therapy?

A

Dialysis
Hemodialysis (HD) — Intermittent HD
Peritoneal Dialysis (PD)
Continuous Renal Replacement Therapy (CRRT) –> Never used chronically

Kidney transplant
Preferred option for eligible patients (Reason: Mortality following kidney transplant is lower than those receiving dialysis)
Subject to organ availability

205
Q

What is a last resort option in ESRD if cannot do dialysis or kidney transplant?

A

Conservative, palliative care – manage the complications as best they can and live out life until death

206
Q

What is the most common dialysis?

A

Hemodialysis is the most common

207
Q

Dialysis Cost

A

Costs about 100,000 dollars a year to put someone through dialysis

208
Q

When is RRT initiated in CKD?

A

No set GFR at which RRT required (more guided by clinical status of pt)

Based on clinical status of the patient

209
Q

KDIGO recommendations for RRT in CKD?

A

Serositis (e.g., pericarditis- urea build up), acid-base or electrolyte abnormalities, pruritus
Inability to control volume status or BP (continuously fluid overloaded)
Malnutrition refractory to dietary intervention
Cognitive impairment (as a result of uremia)

210
Q

At what GFR is dialysis commonly required?

A

Most patients require RRT at GFR ~ 10 mL/min

211
Q

What is the main cause for dialysis in CKD? AKI?

A

Pt;s with CKD have to initiate dialysis due to uremia; where as AKI dialysis is more often due to issues with potassium or metabolic acidosis

212
Q

Most RRT Modality

A

Hemodialysis

213
Q

Hemodialysis MOA

A

Patient’s blood is passed through an external filter to remove wastes and fluid

Solutes move from the blood across the filter into the dialysis solution down their concentration gradient

Filtered blood is then returned to the patient’s body

Can be done at home or in a dialysis clinic

Replacement of chemicals such as sodium bicarb

214
Q

When is hemodialysis conducted?

A

Usually conducted 3x per week at the clinic

3-5 hours for each visit

215
Q

Benefits of Home Dialysis

A

Do it daily, connect themselves daily over night

Slower flow rate and better tolerated

216
Q

What does hemodialysis require for conduction?

A

Requires chronic vascular access that can withstand high blood-flow rates

Arteriovenous (AV) fistula (Preferred method – connect vein and artery mechanically)

Insertion of a synthetic AV graft

Catheter in neck –> Highest risks of complications

217
Q

What other med is needed in hemodialysis?

A

To prevent blood from clotting in the dialysis machine, patients require systemic anticoagulation during the procedure

218
Q

Hemodialysis Cautions

A

Massive fluid shifts during dialysis make patients more prone to hypotension (removing significant volumes of blood)

219
Q

Common Complications of Hemodialysis

A

Common: fatigue, hypotension, hypertension, cramps, N/V

Vascular access problems
Infection
Clotting
Bleeding
(More common with catheter than fistula)

220
Q

Special Considerations of Hemodialysis.Avoid? Monitor?

A

Water soluble vitamins are removed during treatment

All dialysis patients require a water-soluble vitamin formulation

Replavite® tablets (“renal vitamin”) – 1 tab PO daily

Avoid multivitamins containing minerals, vitamin A or D

Monitoring: serum folate, vitamin B12 every 6-12 months

221
Q

replavite

A

Replavite is really on its own; not interchangeable

Questionable how beneficial/necessary it is clinical

May be used in non dialysis CKD pt’s as well

All the B vitamins including biotin, small amount of vitamin C

Vitamin C in excess –> Form kidney stones, careful in these pt’s

Smaller quantities then seen in average multivitamins

222
Q

Peritoneal Dialysis relies on…. MOA

A

Relies on the patient’s own peritoneal membrane to act as a filter for fluid and wastes

2-3L of dialysate is instilled in the peritoneal cavity through an indwelling catheter in the abdominal wall

Wastes and fluid diffuse across the peritoneal membranes down their concentration gradient

Dialysate is drained and replaced with fresh solution

223
Q

Is peritoneal dialysis as efficient a shemodialysis?

A

Because blood is not in direct contact with membrane; less efficient

Has to occur daily, multiple times through a day

224
Q

Types of peritoneal dialysis

A

Continuous Ambulatory Peritoneal Dialysis (CAPD)
Manual exchange, usually 4-5 x per day.
Each exchange takes 30-45 minutes

Automated Peritoneal Dialysis (APD)
Automated – using a machine (called a ‘cycler’) while you sleep
Takes 8-10 hours
May also require manual exchange of fluid in abdomen during the day

225
Q

Advantage of Peritoneal Dialysis

A

Significant freedom; away from clinic, have flexibility

Typically only coming into CKD clinic every 1-2 months

226
Q

Clinical Benefit of Peritoneal Dialysis

A

Preserves residual kidney function; associated with better clinical outcomes in regards to mortality and other things as well

227
Q

Who is peritoneal dialysis good for? Who not?

A

May be preferable in patients continuing to work, travel, etc.

Less regimented schedule than HD

Patients must be able to perform self-care activities (adherent pt’s; unfortunately can be a significant challenge, training, etc.)

228
Q

Complication of peritoneal dialysis and treatment

A

Most frequent complication = Peritonitis

Inflammation and infection of the peritoneal lining

Treated with local or systemic antibiotics

229
Q

CRRT Use

A

Used in acute (intensive care) settings

Not suitable for chronic RRT

For patients who cannot tolerate the abrupt fluid shifts with intermittent HD (cannot be taking that much fluid off at once)

Recommended for hemodynamically unstable patients requiring RRT for an AKI

PHAR 255 Exam 1 (8 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions